AtriCure Inc. (NASDAQ:ATRC) Director Elizabeth D. Krell sold 10,000 shares of AtriCure stock in a transaction dated Tuesday, March 13th. The stock was sold at an average price of $20.00, for a total value of $200,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of AtriCure Inc. (NASDAQ ATRC) traded up $0.20 on Wednesday, hitting $20.19. The stock had a trading volume of 109,957 shares, compared to its average volume of 250,203. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.87 and a current ratio of 2.58. The firm has a market cap of $696.03, a P/E ratio of -25.24 and a beta of 0.30. AtriCure Inc. has a 12 month low of $14.88 and a 12 month high of $25.18.
AtriCure (NASDAQ:ATRC) last issued its earnings results on Monday, February 26th. The medical device company reported ($0.08) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.13. The company had revenue of $46.06 million during the quarter, compared to the consensus estimate of $45.85 million. AtriCure had a negative return on equity of 16.74% and a negative net margin of 15.39%. The firm’s revenue for the quarter was up 11.8% compared to the same quarter last year. During the same period last year, the business posted ($0.27) EPS. equities research analysts predict that AtriCure Inc. will post -0.83 earnings per share for the current fiscal year.
Several research analysts have recently weighed in on ATRC shares. Canaccord Genuity lifted their price objective on AtriCure from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Needham & Company LLC reissued a “buy” rating and issued a $23.00 price objective on shares of AtriCure in a research report on Tuesday, February 27th. Piper Jaffray Companies reissued a “buy” rating and issued a $24.00 price objective on shares of AtriCure in a research report on Sunday, December 10th. TheStreet lowered AtriCure from a “c-” rating to a “d+” rating in a research report on Wednesday, November 29th. Finally, ValuEngine raised AtriCure from a “sell” rating to a “hold” rating in a research report on Wednesday, March 7th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. AtriCure presently has an average rating of “Buy” and an average price target of $24.67.
Several institutional investors and hedge funds have recently modified their holdings of the company. California Public Employees Retirement System grew its stake in shares of AtriCure by 4.3% in the 2nd quarter. California Public Employees Retirement System now owns 36,100 shares of the medical device company’s stock valued at $875,000 after buying an additional 1,500 shares during the period. Schwab Charles Investment Management Inc. boosted its stake in AtriCure by 1.7% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 173,033 shares of the medical device company’s stock valued at $3,157,000 after purchasing an additional 2,932 shares during the last quarter. Macquarie Group Ltd. boosted its stake in AtriCure by 3.9% during the 3rd quarter. Macquarie Group Ltd. now owns 82,245 shares of the medical device company’s stock valued at $1,840,000 after purchasing an additional 3,056 shares during the last quarter. Essex Investment Management Co. LLC boosted its stake in AtriCure by 2.4% during the 4th quarter. Essex Investment Management Co. LLC now owns 145,258 shares of the medical device company’s stock valued at $2,650,000 after purchasing an additional 3,460 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in AtriCure by 1.8% during the 3rd quarter. Bank of New York Mellon Corp now owns 203,273 shares of the medical device company’s stock valued at $4,547,000 after purchasing an additional 3,580 shares during the last quarter. Institutional investors own 87.50% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Elizabeth D. Krell Sells 10,000 Shares of AtriCure Inc. (ATRC) Stock” was published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.thelincolnianonline.com/2018/03/14/elizabeth-d-krell-sells-10000-shares-of-atricure-inc-atrc-stock.html.
AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.